Is Ozempic Stronger Than Wegovy — or Is It the Other Way Around?

Are Ozempic and Wegovy the same drug?

Chemically, yes. Both contain semaglutide, a GLP-1 receptor agonist developed by Novo Nordisk. It works by mimicking a hormone your gut releases after eating, signalling to the brain that you're full and slowing how quickly the stomach empties. The molecule itself is identical in both products.

But identical chemistry does not mean identical medicine. Ozempic was approved and developed for type 2 diabetes; its licensed doses in the UK go up to 1mg weekly (with a 2mg dose available in some circumstances for diabetes management). Wegovy was developed specifically for weight management, with a titration schedule that climbs from 0.25mg up to a 2.4mg maintenance dose, and, as of April 2026, up to a licensed 7.2mg dose for eligible patients. The semaglutide overview on this site explains the full picture of how the drug class works.

So when people ask whether Wegovy is stronger than Ozempic, the honest answer is: at the doses used for weight management, yes, Wegovy operates at a higher dose. But framing it purely as a strength contest misses the point. These are different licensed products, and the law around prescribing them reflects that.

Why can't Ozempic be prescribed for weight loss in the UK?

This is one of the questions our prescribers hear regularly, and it's a fair one, given the two medicines share a molecule. The answer comes down to licensing. The MHRA licences each medicine for the specific indication it was tested and approved for. Ozempic's UK licence covers type 2 diabetes. Using it for weight loss would be an off-label prescription, and the MHRA has been explicit that GLP-1 medicines are not assessed for quick or cosmetic weight loss. You can read the MHRA's own guidance in the NHS's semaglutide medicines information.

There's a practical safety dimension here too. The clinical trials behind Wegovy's approval involved specific titration schedules, monitoring protocols, and patient populations that Ozempic's approval did not. A prescriber issuing Ozempic for weight loss would be working outside the evidence base those licensing decisions rest on.

If you've seen Ozempic offered online for weight loss without a prescription, that's a significant red flag. Prescription-only medicines sold that way fall outside the legal supply chain, and the MHRA has warned repeatedly about counterfeit and unregulated products circulating through social media and unofficial sellers.

What IS licensed for weight loss, and how does it compare to Ozempic's dose?

Two injectable treatments are currently licensed for weight management in the UK: Wegovy (semaglutide) and Mounjaro (tirzepatide). If you're researching whether one semaglutide product is stronger than another, it's worth comparing Wegovy against Saxenda as well as understanding the actual evidence behind these options.

In the STEP 1 clinical trial, published in the New England Journal of Medicine, adults taking semaglutide 2.4mg weekly achieved an average weight reduction of around 15% over 68 weeks alongside lifestyle changes. Wegovy's newer 7.2mg dose (the single-dose pen approved in April 2026) reported around 20.7% average loss over 72 weeks in trials, putting it closer to tirzepatide's results. For anyone wondering what medicines are considered stronger than semaglutide, tirzepatide is the current answer from the clinical evidence.

Mounjaro works differently from Wegovy: it activates both GLP-1 and GIP receptors, whereas semaglutide targets GLP-1 alone. In the SURMOUNT-5 head-to-head trial (published 2025), tirzepatide produced greater average weight reduction than semaglutide 2.4mg over 72 weeks. Which of these suits a particular person is a clinical decision, it depends on health history, other medicines, and how your body responds.

If you'd like to explore what treatment might be appropriate for you, our weight-loss treatment overview covers the licensed options in plain terms. Private pricing information is available on the treatment page.

Is Wegovy stronger than Ozempic for practical purposes, should you switch?

If you're currently on Ozempic for diabetes, changing medicines is a conversation with your diabetes team, not something to arrange through a weight-loss service. The management of type 2 diabetes involves careful monitoring that falls under your GP or endocrinologist's remit.

If you're not diabetic and you've been taking Ozempic from an unregulated source because Wegovy was unavailable or more expensive, you're in a complicated situation. The two medicines aren't interchangeable without clinical oversight, dose equivalence isn't straightforward, and switching requires a prescriber who can assess the full picture.

Some people do transfer from another provider's semaglutide prescription to a regulated service, and that's entirely possible through a proper consultation. You'd be asked for evidence of your current treatment and dose before any continuation. Our frequently asked questions cover how transfers work in more detail.

The short version: Wegovy and Ozempic are not interchangeable over-the-counter products. One is licensed for weight management; the other is not. That distinction matters clinically, legally, and practically, and if you're approaching your target and want to understand what to do when you reach your goal weight on Wegovy, the label it came with still applies.